BR112013012057B1 - Compostos de lipoil e seu uso para o tratamento de lesões isquêmicas - Google Patents

Compostos de lipoil e seu uso para o tratamento de lesões isquêmicas Download PDF

Info

Publication number
BR112013012057B1
BR112013012057B1 BR112013012057-6A BR112013012057A BR112013012057B1 BR 112013012057 B1 BR112013012057 B1 BR 112013012057B1 BR 112013012057 A BR112013012057 A BR 112013012057A BR 112013012057 B1 BR112013012057 B1 BR 112013012057B1
Authority
BR
Brazil
Prior art keywords
ischemia
alkyl
aryl
compound
substituted
Prior art date
Application number
BR112013012057-6A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013012057A2 (pt
Inventor
Alexander B. Baguisi
Reinier Beeuwkes
Ralph Casale
Steven A. Kates
Alan S. Lader
Original Assignee
Ischemix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ischemix Llc filed Critical Ischemix Llc
Publication of BR112013012057A2 publication Critical patent/BR112013012057A2/pt
Publication of BR112013012057B1 publication Critical patent/BR112013012057B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/04Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • C07K5/06113Asp- or Asn-amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112013012057-6A 2010-11-18 2011-11-10 Compostos de lipoil e seu uso para o tratamento de lesões isquêmicas BR112013012057B1 (pt)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US41524110P 2010-11-18 2010-11-18
US41524010P 2010-11-18 2010-11-18
US61/415,240 2010-11-18
US61/415,241 2010-11-18
US201161478310P 2011-04-22 2011-04-22
US61/478,310 2011-04-22
US201161500974P 2011-06-24 2011-06-24
US61/50,974 2011-06-24
US61/500,974 2011-06-24
PCT/US2011/060259 WO2012067947A1 (en) 2010-11-18 2011-11-10 Lipoyl compounds and their use for treating ischemic injury

Publications (2)

Publication Number Publication Date
BR112013012057A2 BR112013012057A2 (pt) 2020-08-04
BR112013012057B1 true BR112013012057B1 (pt) 2021-11-09

Family

ID=45217651

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012057-6A BR112013012057B1 (pt) 2010-11-18 2011-11-10 Compostos de lipoil e seu uso para o tratamento de lesões isquêmicas

Country Status (15)

Country Link
US (2) US8815937B2 (enExample)
EP (1) EP2640423B1 (enExample)
JP (3) JP2014502264A (enExample)
KR (1) KR20140020840A (enExample)
CN (1) CN103561770B (enExample)
AU (1) AU2011329215C1 (enExample)
BR (1) BR112013012057B1 (enExample)
CA (1) CA2817362C (enExample)
DK (1) DK2640423T3 (enExample)
ES (1) ES2640474T3 (enExample)
IL (1) IL226258A (enExample)
MX (1) MX344933B (enExample)
NZ (1) NZ610378A (enExample)
SG (1) SG190794A1 (enExample)
WO (1) WO2012067947A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541396B2 (en) 2009-04-24 2013-09-24 National University Of Singapore Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
WO2012067947A1 (en) 2010-11-18 2012-05-24 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
ITFI20120170A1 (it) * 2012-08-28 2014-03-01 Consorzio Interuniversitario Nazion Ale Per La Sci Nuovi composti ad azione anti-allodinica ed anti-iperalgesica.
JP2017509617A (ja) * 2014-02-27 2017-04-06 コンソルツィオ インターユニヴァーシタリオ ナチオナーレ ペル ラ シエンツァ エ テクノロジア デイ マテリアーリ 抗異痛活性および抗痛覚過敏活性を有する新規化合物
WO2015174948A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations comprising lipoyl compounds
EP3429577B1 (en) * 2016-03-14 2021-12-29 NeoStrata Company, Inc. N-lipoic -amino acid or peptide, derivatives and their uses
RU2657820C1 (ru) * 2017-03-13 2018-06-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ 4-(4-Ацетоксибензоиламино)бутаноилглицин, обладающий церебропротекторным действием при ишемии головного мозга
US10744115B2 (en) 2017-04-25 2020-08-18 Ischemix Llc Compositions and methods for treating traumatic brain injury
US20240124520A1 (en) * 2019-10-16 2024-04-18 The Board Of Trustees Of The Leland Stanford Junior University N-acylated histidine dipeptides as anticancer agents
US11306076B2 (en) * 2020-05-11 2022-04-19 Xi'an Taikomed Pharmaceutical Technology Co., Ltd. Silibinin lipoic acid ester with hepatoprotective activity and a method of preparing the same
CN116199666B (zh) * 2023-03-07 2025-02-28 中国药科大学 两亲性化合物及其药物组合物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875207A (en) 1967-01-25 1975-04-01 Ciba Geigy Corp Process for the temporary protection of amino groups in peptide syntheses
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
CA1219824A (en) 1981-04-17 1987-03-31 David C. Ward Modified nucleotides and methods of preparing and using same
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5288706A (en) 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
FR2653334B1 (fr) * 1989-10-19 1991-12-20 Erphar Ste Civile Preparation cosmetique de bronzage.
EP0812590A3 (de) 1989-11-09 1999-06-09 ASTA Medica Aktiengesellschaft Verwendung von R-Alpha-Liponsäure zur Zytoprotektion
DE4000397A1 (de) 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
EP0639989B1 (en) 1992-04-24 2001-06-27 Biocompatibles Limited Method of reducing microorganism adhesion
EP0838472A4 (en) 1995-06-21 2000-02-02 Asahi Chemical Ind LOW DENSITY LIPOPROTEIN BINDING PEPTIDES
JPH0990542A (ja) 1995-09-28 1997-04-04 Konica Corp ハロゲン化銀写真感光材料
FR2741075B1 (fr) 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques, leur utilisation a titre de medicament et compositions les contenant
CA2264485A1 (en) 1996-09-06 1998-03-12 St. Elizabeth's Medical Center Of Boston, Inc. Gata-6 transcription factor: compositions and methods
JPH11269170A (ja) * 1997-04-02 1999-10-05 Sankyo Co Ltd ジチオラン誘導体
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
JPH117099A (ja) 1997-06-13 1999-01-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US6090842A (en) 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs
JP2000169371A (ja) * 1998-10-02 2000-06-20 Sankyo Co Ltd ジチオラン誘導体を含有する医薬
EP1133317A1 (de) 1998-11-26 2001-09-19 Pentapharm AG Transportsystemkonjugate
WO2001009118A2 (en) 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
JP2003518477A (ja) 1999-11-18 2003-06-10 セレメディックス,インク. 反応性酸素種およびフリーラジカルの効力を中和するための組成物および方法
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
JP2002189271A (ja) 2000-12-21 2002-07-05 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料およびその処理方法
US7700080B2 (en) 2001-03-19 2010-04-20 Senju Pharmaceutical Co., Ltd. Method of suppressing melanin production by metal chelates of lipoyl amino acid derivatives
EP1521735A2 (en) 2001-05-25 2005-04-13 Ceremedix, Inc Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
JP4259813B2 (ja) * 2001-05-29 2009-04-30 千寿製薬株式会社 α−リポイルアミノ酸の安定化法および安定化されたα−リポイルアミノ酸を含有する水性液剤
DE10163836A1 (de) 2001-12-22 2003-07-10 Friz Biochem Gmbh Multifunktionales Reagenz zur Synthese von thiolmodifizierten Oligomeren
WO2003055853A1 (en) 2001-12-26 2003-07-10 Nippon Soda Co., Ltd. Electron-accepting compounds capable of forming self-assembled monolayers
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
WO2003072052A2 (en) 2002-02-22 2003-09-04 Albany College Of Pharmacy Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
JP2003286168A (ja) 2002-03-28 2003-10-07 Senju Pharmaceut Co Ltd α−リポイルアミノ酸を含有する皮膚外用剤
JP4376540B2 (ja) 2002-05-31 2009-12-02 アイバイツ株式会社 金属表面修飾剤および新規含硫黄化合物
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
EP1454627A1 (en) 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
US20040204340A1 (en) 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
US8088935B2 (en) 2003-12-23 2012-01-03 Ironwood Pharmaceuticals, Inc. Compounds and methods for the treatment of asthma
US8765384B2 (en) 2004-02-18 2014-07-01 Japan Science And Technology Agency Carbohydrate-ligand conjugates and their application for the analysis of carbohydrate-protein interaction
JP2006022066A (ja) * 2004-07-09 2006-01-26 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
WO2006101909A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Combination therapy for treating or preventing diseases
WO2006101910A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems
JP2008174453A (ja) 2005-04-28 2008-07-31 Iwaki Kk 頭皮脱毛治療剤
EP1957093B1 (en) 2005-08-29 2017-04-12 SHASHOUA, Victor E. Neuroprotective and neurorestorative methods and compositions
JP4951226B2 (ja) 2005-09-08 2012-06-13 立山化成株式会社 α−リポ酸アルカリ塩の製法
EP1940419A2 (en) 2005-09-09 2008-07-09 Oregon Health and Science University Neuroprotectants
DE602006013787D1 (de) 2006-03-28 2010-06-02 Epitech Group Srl Eine Pharmazeutische Zusammensetzung zur Behandlung von Pathologien, die durch die allgemeine Immunantwort verursacht werden
US20110212954A1 (en) * 2008-11-07 2011-09-01 Mario Brufani Alpha-lipoic acid derivatives and their use in drug preparation
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
PT2821405E (pt) * 2009-06-15 2016-06-14 Encore Health Llc Ésteres de colina para tratar a presbiopia e a catarata
WO2010147957A2 (en) 2009-06-15 2010-12-23 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
IT1397154B1 (it) 2010-01-04 2013-01-04 Ghelardini Composti ad efficacia sia analgesica che antiperalgesica.
WO2012067947A1 (en) 2010-11-18 2012-05-24 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
US20150329519A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations Comprising Lipoyl Compounds

Also Published As

Publication number Publication date
IL226258A0 (en) 2013-07-31
US9359325B2 (en) 2016-06-07
CA2817362A1 (en) 2012-05-24
DK2640423T3 (en) 2017-10-02
EP2640423A1 (en) 2013-09-25
NZ610378A (en) 2015-05-29
JP2016033157A (ja) 2016-03-10
US20130237483A1 (en) 2013-09-12
JP6280094B2 (ja) 2018-02-14
CA2817362C (en) 2018-10-23
SG190794A1 (en) 2013-07-31
US8815937B2 (en) 2014-08-26
US20150065564A1 (en) 2015-03-05
ES2640474T3 (es) 2017-11-03
BR112013012057A2 (pt) 2020-08-04
MX344933B (es) 2017-01-11
CN103561770A (zh) 2014-02-05
KR20140020840A (ko) 2014-02-19
WO2012067947A1 (en) 2012-05-24
MX2013005508A (es) 2013-07-17
EP2640423B1 (en) 2017-07-26
CN103561770B (zh) 2016-11-09
IL226258A (en) 2017-02-28
AU2011329215B2 (en) 2016-04-28
AU2011329215C1 (en) 2016-08-11
JP2018016652A (ja) 2018-02-01
JP2014502264A (ja) 2014-01-30
AU2011329215A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
BR112013012057B1 (pt) Compostos de lipoil e seu uso para o tratamento de lesões isquêmicas
ES2470673T3 (es) Composiciones y métodos para el tratamiento de la isquemia y de la lesión por isquemia y reperfusi�n
JP5380069B2 (ja) フラボノイド化合物およびその使用
ES2340488T3 (es) Sales derivadas del acido lipoico y su utilizacion para el tratamiento de las enfermedades.
AU784840B2 (en) Treatment of cerebrovascular disease
BR112012029975B1 (pt) peptídeo e composição farmacêutica como medicamento
RS58108B1 (sr) Lipidi za formulacije za dostavu terapeutskih agenasa
JPH08508295A (ja) 細胞への浸透増進プロドラッグ
BR9814053B1 (pt) diésteres lipofìlicos de agentes de quelação.
ITMI951357A1 (it) Derivati antrachinonmono- e disolfon- sostituiti e composizioni farmaceutiche che li contengono per il trattamento delle patologie
AU2002218431A1 (en) Perturbed membrane-binding compounds
EP1401420A2 (en) Perturbed membrane-binding compounds
JP2919870B2 (ja) 肝障害抑制剤
WO2008135743A1 (en) Substituted phosphonates and their use in decreasing amyloid aggregates
HK1189803B (en) Lipoyl compounds and their use for treating ischemic injury
HK1189803A (en) Lipoyl compounds and their use for treating ischemic injury
JP6768868B2 (ja) 心筋再生を促進させるための化合物、その調製方法及びこれらの使用
EP3725763A1 (en) Myocardial regeneration promoting compounds, preparation method thereof, pharmaceutical composition, and their use

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 47/48 , C07K 5/06 , C07D 339/04

Ipc: A61K 31/385 (2006.01), A61K 47/50 (2017.01), A61K

B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/11/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.